Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/306% above fair value

$16.42−0.09 (-0.55%)

Close on Nov 13, 2026Market cap $892.71MP/E –Yield –

Beta Bionics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Beta Bionics's enterprise value was $620.63M on Nov 11, 2026, against $1.15B a year earlier.

Period	Period end	Value	Change
2026	Nov 11, 2026	$620.63M	-44.2%
2025	Dec 31, 2025	$1.11B	–

Parsed from the XBRL in Beta Bionics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBNX.

Revenue growth43.7% · median 13.3%

Gross margin58.6% · median 57.6%

Operating margin-72.7% · median -2.1%

Net margin-65.3% · median -1.4%

Advertisement
300 × 250

See a number that looks wrong?